Cholangiocarcinoma (bile duct cancer) · line 2 · Pemigatinib monotherapy (FIGHT-202) — 2L+ FGFR2-fusion cholangiocarcinoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-PEMIGATINIB-CHOLANGIO`

ID	`IND-CHOLANGIO-2L-FGFR2-FUSION-PEMIGATINIB`
Type	Indication
Status	reviewed 2026-04-30 \| pending_clinical_signoff
Diseases	`DIS-CHOLANGIOCARCINOMA`
Sources	`SRC-ESMO-BTC-2023` `SRC-FIGHT-202` `SRC-NCCN-HEPATOBILIARY`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for FGFR2-fusion CCA. NCCN cat 2A (2025); FDA Apr 2020. SRC-FIGHT-202 source stub in KB — citation detail (Abou-Alfa Lancet Oncol 2020, PMID 32203698) pending verification + ingest. UA access: named-patient pathway only.

Used By

Algorithms

ALGO-CHOLANGIO-2L - ALGO-CHOLANGIO-2L

Indication

IND-CHOLANGIO-2L-FUTIBATINIB - IND-CHOLANGIO-2L-FUTIBATINIB
IND-CHOLANGIO-2L-INFIGRATINIB - IND-CHOLANGIO-2L-INFIGRATINIB